

ALMIRALL REACHES AN AGREEMENT TO IMPLEMENT THE REESTRUCTURING PLAN IN SPAIN.

- Both parties have reached a negotiated solution given the situation of the pharmaceutical market and the moment that the company is facing in Spain.

Barcelona, 3rd of February 2014

Almirall and the representatives of the employees have signed an agreement which specifies the conditions to accomplish the company's proposed restructuring plan in Spain, which affects 180 people and aims to balance the company's resources to optimize the potential of its portfolio of existing and new products.

With our respect for the people finally affected by this restructuring plan, Almirall wants to thank all the parties for the efforts made to reach an agreement.

About Almirall

Almirall is a pharmaceutical Company committed to provide valuable medicines through our own R&D efforts, which exceeded 23% on sales in 2012, together with external partnerships, licences and collaborations. Through seeking innovative medicines we aim to become a relevant player in respiratory and dermatology diseases, with also a strong interest in gastroenterology and pain. With more than 3,000 employees in 22 countries, Almirall generated total revenues of 900 million in 2012.

The company was founded in 1943 and is headquartered in Barcelona, Spain. The stock is traded in the Spanish Stock Exchange (ticker: ALM).

For more information please visit: www.almirall.com

More Information:

LLORENTE&CUENCA

Ariadna Carbonell
acarbonell@llorenteycuenca.com
Phone: 00 34 93 217 22 17
Mobile: 00 34 606589136

Eva Pedrol
epedrol@llorenteycuenca.com
Phone: 00 34 93 217 22 17
Mobile: 00 34 679 269 048

Relaciones con Inversores

Jordi Molina
jordi.molina@almirall.com
Phone: 00 34 93 291 30 87